DSGN
Design Therapeutics, Inc.Company with tickers: DSGN
CIK
1807120
CUSIP
25056L103
Shares Outstanding
62,456,974
13F Activity (30d)
37 filings
37 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2026-03-31 | 10-Q | 2026-04-28 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $19,706,000 | USD | 2026-03-31 | 10-Q | 2026-04-28 |
| Research & Development | $14,379,000 | USD | 2026-03-31 | 10-Q | 2026-04-28 |
| Operating Income | $-19,706,000 | USD | 2026-03-31 | 10-Q | 2026-04-28 |
| Net Income | $-17,636,000 | USD | 2026-03-31 | 10-Q | 2026-04-28 |
| EPS (Basic) | $-0.29 | USD/shares | 2026-03-31 | 10-Q | 2026-04-28 |
| EPS (Diluted) | $-0.29 | USD/shares | 2026-03-31 | 10-Q | 2026-04-28 |